Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
MabThera (rituximab)-Important Safety Information from Roche on rituximab and PML, following approval by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
07/11/2008
Problem Or Issue:
Please find hereunder an important safety communication from Roche with respect to rituximab (MabThera) and Progressive Multifocal Leukoencephalopathy (PML) in patients treated for Autoimmune diseases including Rheumatoid Arthritis.
Important Safety Information-MabThera (rituximab)
« Back
Date Printed: 20/05/2024